期刊文献+

女性心血管疾病药物治疗的特点 被引量:2

Cardiovascular drug therapy in women
下载PDF
导出
摘要 随着心血管疾病在女性中发病率的逐年升高,女性心血管疾病的药物治疗引起了广泛关注.由于女性心血管疾病的临床特点和病理生理机制具有一定特异性,药物代谢动力学也不同于男性,更好地理解这种性别差异,对临床上选择用药和药物剂量有重要指导意义.本文结合近年来临床试验的结果,对心血管疾病常用药物在女性患者中的治疗作用和不良反应以及造成性别差异的原因等方面进行论述. With the morbidity of cardiovascular disease in women increasing, cardiovascular drug therapy in women has attracted wide concern. Since there are relative differences of the pathophysiology and clinical manifestations of cardiovascular diseases and also drug metabolsms between men and women, to better understand these differences is instructive to choose suitable drugs and decide proper dosages in women. This article is based on the evidences from recent clinical trials to discuss the specific therapeutic effects and side effects of eardiovaseular drugs in women and the reasons of such differences between the two genders.
出处 《中国心血管杂志》 2007年第2期132-134,共3页 Chinese Journal of Cardiovascular Medicine
关键词 女性 心血管疾病 药物治疗 Women Cardiovascular disease Medicine
  • 相关文献

参考文献2

二级参考文献32

  • 1Braunwald E, Amman EM, Beasley JW. ACAE/AHA guidelines for the management of patient with urLstable angina and non ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient with Unstable Angina) [ J ]. J Am COIl Cardiol, 2000, 36 : 970-1062.
  • 2Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study [J ]. Am J Epidemiol, 2002, 156:1070-1077.
  • 3Mering V, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation(WISE) [Clinical investigation and reports] [ J ]. Circulation,2004,109:722-725.
  • 4Pepine CJ, Handberg EM, Ccoper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment for patients with coronary artery disease. The International Verapamil -Trandolapril Study ( INVEST ) : a randomized controlled trial[J]. JAMA, 2003,290 : 2805-2816.
  • 5Hsia J ,Aragaki A, Bloch M, et al. Predictors of angina pectoris versus myocardial infarction from the Women, s Health Initiative Observational Study[ J ]. Am J Cardiol, 2004,93 : 673-678.
  • 6Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy Amjerican women[ J ]. Circulation, 2003,107 : 391-397.
  • 7Marroqdin OC, Kip KE, Kelley BD, et al. Metabolic syndrome modifies the cardiovascular risk associate with angiographic coronary artery disease in women: a report from the Women' s Ischemia Syndrome Evaluation [J]. Circulation, 2004, 109: 714-721.
  • 8Graham MM,Ghali WA, Faris PD, et al. Sex differences in the prognostic importance of diabetes in patients with ischemic heart disease undergoing coronary angiography [ J ]. Diabetes Care,2003,26 : 3142-3147.
  • 9Kip KE,Marroquin OC, Kelley DE, etal. Clinical Importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation(WISE) Study(Clinical investigation and reports) [J ].Circ ulation, 2004,109 : 706 -713.
  • 10Bairey MN,Bonow RO,Sopko G, et al. Current status and future research directions report of the National Heart, Lung and Blood Institute Workshop October 2-4, 2002 Executive Summary (AHA/NHLBI Conference Proceedings) [J ]. Circulation, 2004,109 : 805-807.

共引文献346

同被引文献12

  • 1Dagenais G R,Pogue J,Fox K,et al.Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure:a combined analysis of three rials[J].Lancet,2006,368(9535):581-588.
  • 2Rat hore S S,Wang Y,Krumholz H M.Sex-based differences in the effect of digoxin for the treatment of heart failure[J].N Engl J Med,2002,347(18):1403-1411.
  • 3Jochmann N,Stangl K,Garbe E,et al.Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases[J].Eur Heart J,2005,26(16):1585-1595.
  • 4Fernandez J R,Hermida R C,Calve C.Chronotherapy increases blood pressure(BP)control and reduces the prevalence of nondipping in patients with essential hypertension[J].Acta Pharmacol Sin,2006,27(Suppl 1):135.
  • 5Hermida R C,Calvo C,Ayala D E.Chronotherapy with blood pressure lowering medications[J].Acta Pharmacol Sin,2006,27(Suppl 1):49.
  • 6Fernandes L S,Tcheng J E.Is glycoprotein Ⅱ b/Ⅲ a antagonism as effective in women as in men following percutaneous coronary intervention?[J].J Am Coll Cardiol,2002,40(6):1085-1091.
  • 7尹建明.非洛地平与卡托普利联用治疗原发性高血压临床观察[J].中国现代医生,2007,45(09S):61-61. 被引量:4
  • 8钱剑安.关注与心血管药物联合应用的严重不良反应[J].中国心血管杂志,2008,13(4):249-251. 被引量:12
  • 9王永志,陈炜,黄大信,许建华,梁雅,高华.钙拮抗剂与血管紧张素转换酶抑制剂对高血压靶器官的影响[J].中华心血管病杂志,1998,26(1):33-36. 被引量:50
  • 10张朝新,姜安军.常用心血管药物在老年人中的应用问题[J].新疆医学,2009,38(4):92-94. 被引量:4

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部